Menstrual migraine: a double-blind trial of percutaneous estradiol
- 1 January 1988
- journal article
- clinical trial
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 2 (2) , 113-120
- https://doi.org/10.3109/09513598809023619
Abstract
The present study investigated whether administration of percutaneous estradiol for the 7 days encompassing menstruation (the paramenstruum) would be effective in alleviating menstrual migraine. The study was a double-blind cross-over placebo comparison of percutaneous estradiol in gel form. Twenty-two women who suffered from regular recurring menstrual migraine were studied during 2 assessment menstrual cycles, 4 treatment cycles (2 of estradiol gel, 2 of placebo gel), and 1 follow-up (no treatment) cycle. Women completed daily records of the occurrence and severity of migraine and medication used. Eighteen women completed the study. There was a significant reduction in the frequency of migraine in the paramenstruum and in the amount of medication taken during use of percutaneous estradiol. Women expressed a significant preference for continuation of therapy with percutaneous estradiol.Keywords
This publication has 8 references indexed in Scilit:
- Prevention of menstrual migraine by percutaneous oestradiol.BMJ, 1986
- Treatment of menstrual migraine by oestradiol implants.Journal of Neurology, Neurosurgery & Psychiatry, 1983
- Pharmacokinetic and pharmacological features of oestradiol valerateMaturitas, 1982
- Absorption of percutaneous oestradiol in postmenopausal womenMaturitas, 1980
- Headache and Sex Hormone TherapyHeadache: The Journal of Head and Face Pain, 1978
- Estrogen‐withdrawal migraineNeurology, 1975
- MIGRAINE AND REPRODUCTIVE HORMONES THROUGHOUT THE MENSTRUAL CYCLEThe Lancet, 1975
- The role of estradiol withdrawal in the etiology of menstrual migraineNeurology, 1972